Get the Stockscreener App
1.04
0.00%
0.00
Omega Therapeutics Inc stock is traded at $1.04, with a volume of 132.02K.
It is up +0.00% in the last 24 hours and down -7.14% over the past month.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
See More
Previous Close:
$1.04
Open:
$1.06
24h Volume:
132.02K
Relative Volume:
0.55
Market Cap:
$57.64M
Revenue:
$3.10M
Net Income/Loss:
$-97.43M
P/E Ratio:
-0.4685
EPS:
-2.22
Net Cash Flow:
$-94.38M
1W Performance:
-16.13%
1M Performance:
-7.14%
6M Performance:
-59.69%
1Y Performance:
-42.54%
1-Day Range:
$1.02
$1.06
1-Week Range:
$1.02
$1.35
52-Week Range:
$0.89
$6.30
Omega Therapeutics Inc Stock (OMGA) Company Profile
Name
Omega Therapeutics Inc
Sector
Industry
Phone
(617) 949-4360
Address
140 FIRST STREET, SUITE 501, CAMBRIDGE
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Sep-23-22 | Initiated | Chardan Capital Markets | Buy |
Omega Therapeutics Inc Stock (OMGA) Latest News
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last? - Yahoo Finance
Zura Bio (NASDAQ:ZURA) versus Omega Therapeutics (NASDAQ:OMGA) Critical Contrast - Defense World
Omega Therapeutics stock hits 52-week low at $0.94 By Investing.com - Investing.com Australia
Cubist Systematic Strategies LLC Grows Holdings in Omega Therapeutics, Inc. (NASDAQ:OMGA) - Defense World
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings - The Manila Times
Omega Therapeutics to Present Multiple Posters Highlighting - GlobeNewswire
Omega Therapeutics stock hits 52-week low at $0.94 - Investing.com
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions - Financial Times
Omega Therapeutics stock hits 52-week low at $1.07 By Investing.com - Investing.com Australia
Omega Therapeutics stock hits 52-week low at $1.07 - Investing.com India
Omega Therapeutics Appoints New Director - Investing.com India
Omega Therapeutics Welcomes Robert Rosiello to Board - TipRanks
Omega Therapeutics Appoints New Director By Investing.com - Investing.com UK
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors – Company Announcement - Financial Times
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore - Financial Times
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer - Financial Times
Omega Therapeutics stock hits 52-week low at $1.2 By Investing.com - Investing.com Canada
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry – Company AnnouncementFT.com - Financial Times
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications - ForexTV.com
Omega Therapeutics reports tumor inhibition in liver cancer models - Investing.com
Omega Therapeutics Announces Publication of Epigenomic - GlobeNewswire
RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting RevenueTechnavio - The Malaysian Reserve
RNA-Based Therapeutics Market To Grow By USD 1.27 Billion (2024-2028) Due To Increased Investment And Funding, AI Trends Impacting RevenueTechnavio - MENAFN.COM
Omega Therapeutics (NASDAQ:OMGA) Stock Price Up 0.8% - MarketBeat
Omega Therapeutics (NASDAQ:OMGA) Shares Up 0.8% - Defense World
Omega Therapeutics stock hits 52-week low at $1.29 amid downturn - Investing.com Australia
A look into Omega Therapeutics Inc (OMGA)’s deeper side - SETE News
Omega Therapeutics inks shared space deals with Flagship affiliates - Investing.com
Omega Therapeutics inks shared space deals with Flagship affiliates By Investing.com - Investing.com South Africa
Novo Nordisk to meet Drug Demand with $220M Expansion - European Pharmaceutical Manufacturer
HC Wainwright Comments on Omega Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:OMGA) - MarketBeat
HC Wainwright Analysts Boost Earnings Estimates for Omega Therapeutics, Inc. (NASDAQ:OMGA) - Defense World
Omega Therapeutics' (OMGA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Omega Therapeutics appoints new SVP of Research By Investing.com - Investing.com Australia
A Glimpse Into The Expert Outlook On Omega Therapeutics Through 4 Analysts - Benzinga
Omega Therapeutics appoints new SVP of Research - Investing.com India
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - GlobeNewswire
Omega Therapeutics Appoints Jennifer Nelson, Ph.D., as Senior Vice President of Research - citybiz
Omega Therapeutics, Inc. (NASDAQ:OMGA) Forecasted to Post FY2024 Earnings of ($1.27) Per Share - MarketBeat
Omega Therapeutics’ (OMGA) “Outperform” Rating Reiterated at Wedbush - Defense World
Middle East & Africa Calcium Carbonate Market Size & Outlook, 2030 - Grand View Research
Wedbush Weighs in on Omega Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:OMGA) - MarketBeat
Q3 2024 EPS Estimates for Omega Therapeutics, Inc. (NASDAQ:OMGA) Decreased by Analyst - Defense World
Omega Therapeutics Inc Stock (OMGA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):